Showing 137 news articles about Injectable & long-acting HIV treatment

Filters Content type: Editors' picks Topic: Injectable & long-acting HIV treatment

Research into injectable medications and other innovative forms of HIV treatment. It is hoped that they may only need to be taken every few weeks or months, rather than daily.

 

Injectable & long-acting HIV treatment

I Stopped Taking My HIV Pills

Editor's pick
POZ
20 January 2023
Injectable & long-acting HIV treatment

Study Bite: Despite Initial Interest, Many Don’t Switch to LA-ART

Editor's pick
TheBodyPro
20 January 2023
Injectable & long-acting HIV treatment

Injectable HIV treatment offers hope to Ugandan patients

Editor's pick
Reuters
26 December 2022
Injectable & long-acting HIV treatment

FDA Approves New HIV Drug for Adults with Limited Treatment Options

Editor's pick
FDA
22 December 2022
Injectable & long-acting HIV treatment

Pregnancy Outcomes on Long-Acting Antiretroviral

Editor's pick
Medscape (requires free registration)
6 December 2022
Injectable & long-acting HIV treatment

Botswana Introduces Injectable Antiretrovirals for HIV Treatment

Editor's pick
AllAfrica
23 November 2022
Injectable & long-acting HIV treatment

Lenacapavir Shows Continued Promise for People With Drug-Resistant HIV

Editor's pick
POZ
10 November 2022
People with limited treatment options

FDA Approves Trogarzo for 30-Second IV Push, Simplifying HIV Treatment for Heavily Treatment-Experienced People

Editor's pick
Infectious Disease Special Edition
5 October 2022
Drug interactions & pharmacokinetics

Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence

Editor's pick
i-Base
3 October 2022
Injectable & long-acting HIV treatment

Compassionate Use of Long-Acting Cabotegravir Plus Rilpivirine in HIV

Editor's pick
Infectious Disease Advisor
26 September 2022
Injectable & long-acting HIV treatment

UNAIDS responds to EU approval of a long acting HIV treatment option: “To end AIDS, share technology.”

Editor's pick
UNAIDS
23 August 2022
Pharmaceutical industry

Gilead bags first approval for twice-yearly HIV therapy

Editor's pick
Pharmaphorum
22 August 2022
Injectable & long-acting HIV treatment

Long-Acting Injectable HIV Therapy for People Who Won’t Take ART?

Editor's pick
NEJM Journal Watch
10 August 2022
Injectable & long-acting HIV treatment

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

Editor's pick
Gilead Sciences press release
25 June 2022
New & experimental HIV treatments

Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120

Editor's pick
GlobeNewswire (press release)
13 June 2022
Drug interactions & pharmacokinetics

ViiV Healthcare has obtained marketing approval for the first and only complete long-acting treatment for HIV in Japan

Editor's pick
ViiV press release
31 May 2022
Injectable & long-acting HIV treatment

Bi-Monthly Injectable HIV-Treatment Drug Cabenuva Listed On Australia's PBS

Editor's pick
Star Observer
1 April 2022
Injectable & long-acting HIV treatment

US: Cabenuva Approval Expanded to Include Adolescents With HIV

Editor's pick
Monthly Prescribing Reference
31 March 2022
Injectable & long-acting HIV treatment

ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period

Editor's pick
ViiV press release
25 March 2022
Injectable & long-acting HIV treatment

US: Bottlenecks are slowing switch to GSK's long-acting HIV injectable Cabenuva: clinician

Editor's pick
FiercePharma
9 March 2022
Injectable & long-acting HIV treatment

Interim BHIVA guidance on long-acting cabotegravir/rilpivirine (LA-CAB/RPV) for antiretroviral therapy

Editor's pick
BHIVA
7 February 2022
Injectable & long-acting HIV treatment

ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment

Editor's pick
ViiV press release
1 February 2022
Injectable & long-acting HIV treatment

Particulate problem prompts hold on 10 Gilead studies of HIV hopeful lenacapavir

Editor's pick
FiercePharma
26 December 2021
Injectable & long-acting PrEP

GlaxoSmithKline's HIV prevention injectable Apretude threatens Gilead with FDA blessing. But will doctors use it?

Editor's pick
FiercePharma
26 December 2021